It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 16.2% in that time frame, outperforming the S&P 500. But investors have to be ...

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 9 Stocks Crushing the Market With Surging Returns. Recursion ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs.

The stock looks cheap, but appearances can be deceiving.

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of ...

Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in an upcoming investor conference: Webcasts may be ...

Recursion stands out as a pure play in AI-powered biotech, using machine learning algorithms to accelerate drug research and development (R&D). The company's BioHive-2 supercomputer, powered by Nvidia ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...